Hypofractionated Low-Dose Radiotherapy Combined with Immune Checkpoint Inhibition in Metastatic Solid Tumors

References

• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III Non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937
   PubMed Web of Science ®Google Scholar
• Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med. 2019;7(4):347–357. doi:10.1016/S2213-2600(18)30500-9
   PubMed Web of Science ®Google Scholar
• Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 2015;365(1):23–29. doi:10.1016/j.canlet.2015.05.012
   PubMed Web of Science ®Google Scholar
• De Lima Lopes G, Wu YL, Sadowski S, et al. P2.43: pembrolizumab vs platinum-based chemotherapy for PD-L1+ NSCLC: phase3, randomized, open-label KEYNOTE-042 (NCT02220894). J Thoracic Oncol. 2016;11(10):S244–S245. doi:10.1016/j.jtho.2016.08.114
   Web of Science ®Google Scholar
• Gillison ML, Blumenschein G, Fayette J, et al. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer. Oncologist. 2018;23(9):1079–1082. doi:10.1634/theoncologist.2017-0674
   PubMed Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label Phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-0
   PubMed Web of Science ®Google Scholar
• Blades RA, Keating PJ, Mcwilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology. 1995;46(5):681–687. doi:10.1016/S0090-4295(99)80301-X
   PubMed Web of Science ®Google Scholar
• Ben-Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J. Hypoxia controls CDd+CD25+regulatory T-cell homeostasis via hypoxia-inducible factor-Ialpha. Eur J Immunol. 2008;38(9):2412–2418. doi:10.1002/eji.200838318
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18(8):1254–1261. doi:10.1038/nm.2883
   PubMed Web of Science ®Google Scholar
• Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181–273. doi:10.1016/s0065-2776(08)60911-6
   PubMedGoogle Scholar
• Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–349. doi:10.1016/j.ijrobp.2012.12.025
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489. doi:10.1038/nature10673
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–5468. doi:10.1158/0008-5472.CAN-14-1258
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi:10.1172/JCI67313
   PubMed Web of Science ®Google Scholar
• Park SS, Dong HD, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):610–619. doi:10.1158/2326-6066.CIR-14-0138
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3(4):345–355. doi:10.1158/2326-6066.CIR-14-0196
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ruiz ME, Rodriguez I, Garasa S, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Can Res. 2016;76(20):5994–6005. doi:10.1158/0008-5472.CAN-16-0549
   PubMed Web of Science ®Google Scholar
• Herter-Sprie GS, Koyama S, Korideck H, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016;1(9):e87415. doi:10.1172/jci.insight.87415
   PubMed Web of Science ®Google Scholar
• Gong XM, Li XF, Jiang T, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12(7):1085–1097. doi:10.1016/j.jtho.2017.04.014
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Mimura K, Yoshimoto Y, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 2012;72(16):3967–3976. doi:10.1158/0008-5472.CAN-12-0851
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Melis MH, Wilkinson RW, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 2013;121(2):251–259. doi:10.1182/blood-2012-05-432393
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498–509. doi:10.1016/S1470-2045(15)00007-8
   PubMed Web of Science ®Google Scholar
• Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol. 2016;1(3):EAAG1266. doi:10.1126/sciimmunol.aag1266
   PubMed Web of Science ®Google Scholar
• Wang SC, Yu CF, Hong JH, Tsai CS, Chiang CS. Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLoS One. 2013;8(8):e69182. doi:10.1371/journal.pone.0069182
   PubMed Web of Science ®Google Scholar
• Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73(9):2782–2794. doi:10.1158/0008-5472.CAN-12-3981
   PubMed Web of Science ®Google Scholar
• Ruffell B, Chang-Strachan D, Chan V, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014;26(5):623–637. doi:10.1016/j.ccell.2014.09.006
   PubMed Web of Science ®Google Scholar
• Barsoumian HB, Ramapriyan R, Younes AI, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020;8(2):e000537. doi:10.1136/jitc-2020-000537
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer im-munotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–265. doi:10.1093/jnci/djs629
   PubMed Web of Science ®Google Scholar
• Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306–1310. doi:10.1016/j.ijrobp.2011.09.049
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of nonsmall-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial [published correction appears in Lancet Oncol. 2017 Jul;18(7): e371]. Lancet Oncol. 2017;18(7):895–903. doi:10.1016/S1470-2045(17)30380-7
   PubMed Web of Science ®Google Scholar
• Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2020;6(6):848–855. doi:10.1001/jamaoncol.2019.6731
   PubMed Web of Science ®Google Scholar
• Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611–1618. doi:10.1200/JCO.2017.76.2229
   PubMed Web of Science ®Google Scholar
• Maity A, Mick R, Huang AC, et al. A Phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer. 2018;119(10):1200–1207. doi:10.1038/s41416-018-0281-9
   PubMed Web of Science ®Google Scholar
• Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020;8(2):e001001. doi:10.1136/jitc-2020-001001
   PubMed Web of Science ®Google Scholar
• Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276–1282. doi:10.1001/jamaoncol.2019.1478
   PubMed Web of Science ®Google Scholar
• Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179. Cancer. 2020;126(19):4353–4361. doi:10.1002/cncr.33083
   PubMed Web of Science ®Google Scholar
• Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2020. doi:10.1016/S2213-2600(20)30391-X
   PubMed Web of Science ®Google Scholar
• Yin L, Xue J, Li R, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2020;108(1):212–224. doi:10.1016/j.ijrobp.2020.05.002
   PubMed Web of Science ®Google Scholar